Q-omics provides the consensus-scored PHKA1 profile across patient tissues and cancer cell-line models. PHKA1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, PHKA1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, PHKA1 protein abundance shows 22,530 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUAD, COAD, and LSCC as cancer lineages where PHKA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHKA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHKA1 survival associations across molecular data types. PHKA1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHKA1 RNA expression–survival associations across cancer types. High PHKA1 expression shows unfavorable associations in LUAD, UCEC, KIRP, KIRC and UCS, but favorable associations in OV. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for PHKA1 RNA expression.
This table summarizes PHKA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PHKA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHKA1 shows higher tumor expression in COAD, KICH, KIRP, LUAD, LUSC and KIRC. The COAD box plot shows higher PHKA1 RNA expression in tumor versus normal tissue (log2 FC = +1.431, t-test p < 0.001).
This table shows molecular features associated with PHKA1 in patient tissues and cancer cell lines. In patient samples, PHKA1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PHKA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
